Urticaria
MONDO:0005492A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.
Also known as: hives, urticaria, urticaria (disease), Urticarias
165 clinical trials for this condition and its sub-types, 28 tagged with Urticaria itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Urticaria
-
Angioedema 19 trials · 66 incl. sub-types
3 sub-types
- Hereditary angioedema 58 trials · 60 incl. sub-types Sub-types →
- Acquired angioedema 2 trials · 3 incl. sub-types Sub-types →
- Non-histaminic angioedema 2 trials
-
Idiopathic urticaria 0 trials · 66 incl. sub-types
2 sub-types
- Chronic idiopathic urticaria 65 trials
- Acute idiopathic urticaria 1 trial
-
Chronic urticaria 12 trials · 20 incl. sub-types
1 sub-type
- Chronic inducible urticaria 8 trials
-
Physical urticaria 3 trials · 15 incl. sub-types
3 sub-types
- Familial dermatographia 12 trials
- Cholinergic urticaria 2 trials
- Vibratory urticaria 0 trials · 2 incl. sub-types Sub-types →
-
Cold urticaria 10 trials
-
Allergic urticaria 3 trials · 5 incl. sub-types
1 sub-type
- Non-histaminic angioedema 2 trials
-
Cutaneous mastocytosis 1 trial
3 sub-types
- Cutaneous mastocytoma 0 trials Sub-types →
- Diffuse cutaneous mastocytosis 0 trials Sub-types →
- Maculopapular cutaneous mastocytosis 0 trials Sub-types →
-
Urticaria, aquagenic 1 trial
-
Melkersson-Rosenthal syndrome 0 trials
-
Autoimmune urticaria 0 trials
-
Papular urticaria 0 trials
Most studied deeper sub-types
-
New pill for stubborn hives shows promise, but trial halted early
Symptom relief Stopped earlyThis Phase 2 trial tested an experimental drug called EP262 in 113 people with chronic spontaneous urticaria (long-lasting hives with no clear cause). Participants took either EP262 or a placebo daily for 6 weeks, while continuing their usual antihistamines. The study aimed to se…
Phase 2 • Sponsor: Escient Pharmaceuticals, Inc • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Experimental shot for Cold-Triggered hives tested, but trial stopped early
Symptom relief Stopped earlyThis early-stage trial tested a single dose of a drug called briquilimab in 27 adults with chronic hives caused by cold or friction that did not improve with standard allergy pills. The main goal was to check safety and see if the drug could reduce symptoms. However, the trial wa…
Phase 1/2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC